In this issue:
European Myeloma Network trial shows a benefit to ASCT and consolidation therapy in NDMM
Day-1 versus day-2 melphalan prior to ASCT in myeloma patients
Are renal biopsies necessary in cases of light chain cast nephropathy?
Ixazomib as post-ASCT maintenance deepens responses and improves PFS compared to placebo
Long-term follow-up results of VRD induction therapy and risk-adapted maintenance approach in NDMM
VMP versus Rd-R for transplant-ineligible MM
1q21 gain and high-risk GEP70 status are negative prognostic factors for response to daratumumab in RRMM
Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with NDMM
Minimal residual disease negativity does not overcome poor prognosis in highrisk MM
The T-cell–redirecting bispecific antibody JNJ-64407564 shows promise for MM
Please login below to download this issue (PDF)